Loading institutional data...
Loading institutional data...
Held by 173 of 5,944 reporting institutions (90th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$9M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 9 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -9%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 9 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $42M covers all $36M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2024-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~7.4% on $36M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 8-yr range · 12th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 8.7 | 10.1 | 12.1 | 11.6 | 14.8 | 21.2 | 21.0 | 20.4 |
| Gross Profit | 91.3 | 89.9 | 87.9 | 88.4 | 85.2 | 78.8 | 79.0 | 79.6 |
| R&D | 9.7 | 10.8 | 12.9 | 13.8 | 12.8 | 10.8 | 9.9 | 8.7 |
| SG&A | 22.8 | 31.2 | 27.0 | 27.8 | 27.2 | 22.4 | 20.2 | 20.2 |
| Operating Income | -21.6 | -53.5 | -52.6 | -57.3 | -56.0 | -33.8 | -21.1 | -11.1 |
| Income Tax | 0.0 | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -31.5 | -57.1 | -59.5 | -62.8 | -57.6 | -31.2 | -18.5 | -9.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SIBN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $200.9M 100.0% | $167.2M 100.0% | $138.9M 100.0% | $106.4M 100.0% | $90.2M 100.0% | $73.4M 100.0% | $67.3M 100.0% | $55.4M 100.0% | $48.0M 100.0% |
| Cost of Revenue | $41.0M 20.4% | $35.1M 21.0% | $29.5M 21.2% | $15.7M 14.8% | $10.4M 11.6% | $8.9M 12.1% | $6.8M 10.1% | $4.8M 8.7% | $5.1M 10.7% |
| Gross Profit | $159.9M 79.6% | $132.1M 79.0% | $109.4M 78.8% | $90.7M 85.2% | $79.7M 88.4% | $64.5M 87.9% | $60.5M 89.9% | $50.5M 91.3% | $42.9M 89.3% |
| Research & Development | $17.4M 8.7% | $16.6M 9.9% | $15.0M 10.8% | $13.6M 12.8% | $12.4M 13.8% | $9.5M 12.9% | $7.3M 10.8% | $5.4M 9.7% | $5.5M 11.5% |
| Selling, General & Admin | $40.5M 20.2% | $33.8M 20.2% | $31.1M 22.4% | $29.0M 27.2% | $25.1M 27.8% | $19.8M 27.0% | $21.0M 31.2% | $12.6M 22.8% | $13.1M 27.2% |
| Total Operating Expenses | $182.2M 90.7% | $167.4M 100.1% | $156.4M 112.6% | $150.3M 141.3% | $131.4M 145.7% | $103.1M 140.4% | $96.5M 143.4% | $62.5M 112.9% | $60.2M 125.5% |
| Operating Income | -$22.3M -11.1% | -$35.2M -21.1% | -$46.9M -33.8% | -$59.6M -56.0% | -$51.7M -57.3% | -$38.6M -52.6% | -$36.0M -53.5% | -$12.0M -21.6% | -$17.4M -36.2% |
| Interest Expense | $2.6M 1.3% | $3.4M 2.1% | $3.5M 2.5% | $2.8M 2.6% | $5.4M 6.0% | $6.1M 8.3% | $4.9M 7.4% | $5.1M 9.2% | $6.2M 12.9% |
| Interest & Investment Income | $6.1M 3.0% | $7.8M 4.7% | $6.9M 5.0% | $1.3M 1.2% | $186K 0.2% | $1.1M 1.5% | $2.6M 3.8% | $769K 1.4% | $175K 0.4% |
| Other Income (Expense), net | -$20K -0.0% | -$73K -0.0% | $141K 0.1% | -$132K -0.1% | $277K 0.3% | -$126K -0.2% | -$2K -0.0% | -$1.1M -2.1% | $340K 0.7% |
| Pretax Income | — | — | — | — | — | -$43.7M -59.5% | -$38.4M -57.1% | -$17.5M -31.5% | -$23.0M -48.0% |
| Income Tax Expense | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | — | — | $0 0.0% | $0 0.0% |
| Net Income | -$18.9M -9.4% | -$30.9M -18.5% | -$43.3M -31.2% | -$61.3M -57.6% | -$56.6M -62.8% | -$43.7M -59.5% | -$38.4M -57.1% | -$17.5M -31.5% | -$23.0M -48.0% |
| Per Share | |||||||||
| EPS (Basic) | $-0.44 | $-0.75 | $-1.13 | $-1.79 | $-1.71 | $-1.50 | — | — | — |
| EPS (Diluted) | $-0.44 | $-0.75 | $-1.13 | $-1.79 | $-1.71 | $-1.50 | — | — | — |
| Weighted Avg Shares (Basic) | 43.0M | 41.5M | 38.4M | 34.2M | 33.1M | 29.1M | — | — | — |
| Weighted Avg Shares (Diluted) | 43.0M | 41.5M | 38.4M | 34.2M | 33.1M | 29.1M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| SIBN | $787M | — | — | 3.9× | 20.2% | 79.6% | -9.4% | -10.6% | -8.9% | -2.1× | 173 |
Peers = companies sharing SIBN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.